This month, Gilead suspended its two Covid-19 trials for the promising antiviral remdesivir for moderate-to-severe patients, citing as the reason that the epidemic of Covid-19 has been so well-controlled in China, no eligible patients can be enrolled at present.
As many other regions beset by Covid-19 have implemented measures to control the outbreak, we must consider that there may not be enough patients with Covid-19 to enrol in studies for interventions. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
